☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Formycon
The EMA Accepts Formycon’s MAA for FYB203 to Treat Neovascular Age-Related Macular Degeneration (AMD)
December 27, 2023
Formycon’s Ranopto Receives Health Canada’s Approval for the Treatment of Several Retinal Diseases
December 7, 2023
Insights+ Key Biosimilars Events of September 2023
October 5, 2023
Formycon Reports the US FDA Acceptance of BLA for FYB203 (biosimilar, aflibercept) to Treat Retinal Diseases
September 1, 2023
Formycon and Fresenius Kabi Settled with Johnson & Johnson for FYB202, a Proposed Biosimilar to Stelara (ustekinumab)
August 7, 2023
Formycon Reports P-III (VESPUCCI) Trial Results of FYB202 (biosimilar, ustekinumab) for the Treatment of Psoriasis Vulgaris
August 16, 2022
Load more...
Back to Home